Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients.
Rituraj UpadhyayBrett KlamerJennifer K MatsuiVikram B ChakravarthyThomas ScharschmidtNicholas YeagerBhuvana A SettyTimothy P CripeRyan D RobertsJennifer H AldrinkRaj SinghRaju R RavalJoshua David PalmerSujith BaligaPublished in: Cancers (2024)
SABR is well tolerated in pediatric patients with 1-year local failure and OS rates of <10% and 70%, respectively. Future studies evaluating SABR in combination with systemic therapy are needed to address progression outside of the irradiated field.